Rigel Pharmaceuticals, Inc. financial reports, Rigel Pharmaceuticals, Inc. annual revenue in 2024. When does Rigel Pharmaceuticals, Inc. report revenue?
Rigel Pharmaceuticals, Inc. total revenue, net income and dynamics of changes in US dollar today
Rigel Pharmaceuticals, Inc. current income in US dollar. Net revenue of Rigel Pharmaceuticals, Inc. on 31/03/2021 amounted to 81 018 000 $. Net income, revenue and dynamics - the main financial indicators of Rigel Pharmaceuticals, Inc.. Schedule of the financial report of Rigel Pharmaceuticals, Inc. for today. The financial graph of Rigel Pharmaceuticals, Inc. shows the values and changes of such indicators: total assets, net income, net revenue. All information on Rigel Pharmaceuticals, Inc. total revenue on this chart is created in the form of yellow bars.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
81 018 000 $
+541.78 % ↑
39 500 000 $
-
31/12/2020
18 450 000 $
-51.264 % ↓
-19 237 000 $
-695.942 % ↓
30/09/2020
18 389 000 $
-11.833 % ↓
-14 174 000 $
-
30/06/2020
16 021 000 $
+53.94 % ↑
-17 576 000 $
-
30/09/2019
20 857 000 $
-
-11 490 000 $
-
30/06/2019
10 407 000 $
-
-20 606 000 $
-
31/03/2019
12 624 000 $
-
-17 598 000 $
-
31/12/2018
37 857 000 $
-
3 228 000 $
-
30/09/2018
4 865 000 $
-
-23 766 000 $
-
30/06/2018
1 787 000 $
-
-25 557 000 $
-
31/03/2018
0 $
-
-24 385 000 $
-
31/12/2017
0 $
-
-25 871 000 $
-
30/09/2017
900 000 $
-
-17 660 000 $
-
30/06/2017
0 $
-
-19 147 000 $
-
Show:
to
Rigel Pharmaceuticals, Inc. financial report charts
The latest dates of Rigel Pharmaceuticals, Inc. financial statements available online: 30/06/2017, 31/12/2020, 31/03/2021. The dates of financial statements are strictly regulated by law and financial statements. The current date of the financial report of Rigel Pharmaceuticals, Inc. for today is 31/03/2021. Gross profit Rigel Pharmaceuticals, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Rigel Pharmaceuticals, Inc. is 63 876 000 $
Rigel Pharmaceuticals, Inc. quarterly report dates
Cost of revenue Rigel Pharmaceuticals, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue Rigel Pharmaceuticals, Inc. is 17 142 000 $ Total revenue Rigel Pharmaceuticals, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Rigel Pharmaceuticals, Inc. is 81 018 000 $ Operating income Rigel Pharmaceuticals, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Rigel Pharmaceuticals, Inc. is 41 755 000 $
Net income Rigel Pharmaceuticals, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Rigel Pharmaceuticals, Inc. is 39 500 000 $ Current assets Rigel Pharmaceuticals, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Rigel Pharmaceuticals, Inc. is 196 758 000 $ Total assets Rigel Pharmaceuticals, Inc. refers to the total amount of assets owned by a person or entity. Total assets Rigel Pharmaceuticals, Inc. is 215 993 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
30/09/2018
30/06/2018
31/03/2018
31/12/2017
30/09/2017
30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
63 876 000 $
2 991 000 $
3 649 000 $
1 528 000 $
6 084 000 $
-3 130 000 $
1 568 000 $
23 902 000 $
-6 301 000 $
-9 040 000 $
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
17 142 000 $
15 459 000 $
14 740 000 $
14 493 000 $
14 773 000 $
13 537 000 $
11 056 000 $
13 955 000 $
11 166 000 $
10 827 000 $
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
81 018 000 $
18 450 000 $
18 389 000 $
16 021 000 $
20 857 000 $
10 407 000 $
12 624 000 $
37 857 000 $
4 865 000 $
1 787 000 $
-
-
900 000 $
-
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
20 857 000 $
10 407 000 $
12 624 000 $
37 857 000 $
4 865 000 $
1 787 000 $
-
-
900 000 $
-
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
41 755 000 $
-18 827 000 $
-13 781 000 $
-17 392 000 $
-12 037 000 $
-21 339 000 $
-18 378 000 $
2 532 000 $
-24 370 000 $
-26 111 000 $
-24 734 000 $
-26 215 000 $
-17 855 000 $
-19 344 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
39 500 000 $
-19 237 000 $
-14 174 000 $
-17 576 000 $
-11 490 000 $
-20 606 000 $
-17 598 000 $
3 228 000 $
-23 766 000 $
-25 557 000 $
-24 385 000 $
-25 871 000 $
-17 660 000 $
-19 147 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
-
-
-
-
-
-
-
46 903 000 $
46 903 000 $
46 903 000 $
11 242 000 $
11 561 000 $
10 808 000 $
11 524 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
39 263 000 $
37 277 000 $
32 170 000 $
33 413 000 $
32 894 000 $
31 746 000 $
31 002 000 $
35 325 000 $
29 235 000 $
27 898 000 $
24 734 000 $
26 215 000 $
18 755 000 $
19 344 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
196 758 000 $
88 983 000 $
99 848 000 $
113 090 000 $
126 002 000 $
124 504 000 $
139 319 000 $
136 987 000 $
121 036 000 $
139 057 000 $
96 620 000 $
117 433 000 $
69 561 000 $
83 792 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
215 993 000 $
110 378 000 $
123 058 000 $
138 035 000 $
156 061 000 $
156 158 000 $
172 784 000 $
139 109 000 $
123 169 000 $
141 219 000 $
98 813 000 $
119 111 000 $
71 250 000 $
85 478 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
20 047 000 $
30 373 000 $
36 567 000 $
36 469 000 $
39 093 000 $
44 229 000 $
74 696 000 $
76 322 000 $
61 486 000 $
65 078 000 $
40 125 000 $
38 290 000 $
25 879 000 $
32 591 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
31 006 000 $
28 380 000 $
26 138 000 $
27 734 000 $
19 696 000 $
17 365 000 $
-
-
-
-
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
-
-
94 300 000 $
115 751 000 $
68 076 000 $
82 302 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
87 150 000 $
77 867 000 $
77 469 000 $
29 232 000 $
19 696 000 $
17 652 000 $
-
-
-
-
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
55.84 %
49.86 %
44.84 %
21.01 %
15.99 %
12.50 %
-
-
-
-
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
78 298 000 $
34 026 000 $
50 955 000 $
63 210 000 $
68 911 000 $
78 291 000 $
95 315 000 $
109 877 000 $
103 473 000 $
123 567 000 $
79 807 000 $
100 646 000 $
56 167 000 $
69 605 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-14 641 000 $
-16 651 000 $
-569 000 $
11 644 000 $
-20 082 000 $
-26 994 000 $
-23 394 000 $
-19 715 000 $
-17 610 000 $
-19 470 000 $
Last revenue report of Rigel Pharmaceuticals, Inc. was 31/03/2021. According to last financial report total revenue in Rigel Pharmaceuticals, Inc. was 81 018 000 US dollar and changed by +541.78% since last year. Net income in Rigel Pharmaceuticals, Inc. was 39 500 000 $ in last quartal, net income changes to -695.942%.
Current cash Rigel Pharmaceuticals, Inc. - the sum of all of the cash a company has on the date of report. Current cash Rigel Pharmaceuticals, Inc. is 20 047 000 $
Rigel Pharmaceuticals, Inc. stocks data
RIGL stock price
Rigel Pharmaceuticals, Inc. stock price today, RIGL stock quote.
